Save 35% + Free Shipping — Single Vials In Stock · code

Back to Catalog

Peptides

KPV 5 mg

$72Per Unit

Lys-Pro-Val synthetic tripeptide exhibiting potent cellular signaling modulation without pigmentary activity. Verified by NMR and HPLC.

Lot KPV2026-09I · COA on request
Lyophilized tripeptide, sterile vial, 5 mg fill
2–8°C

5 × $72.00 = $360.00 $234.00 (35% off with code EHAB35 + free shipping)

Your order of 5 units qualifies: apply code EHAB35 at checkout for 35% off and free shipping.

KPV 5 mg

$234.00 for 5 · 35% off

Research use only
KPV 5 mg research packaging
Lyophilized tripeptide, sterile vial, 5 mg fill
Anubis Research Labs

Documentation

The certificate of analysis for the current lot (Lot KPV2026-09I) is sent on request, so you can review identity and purity testing before you order.

Request the lot COA

Research summary

KPV(Lys-Pro-Val, alpha-MSH C-terminal tripeptide)

Regulatory status
Not approved. FDA reports it has not identified any human exposure data for KPV and lists it among substances that may present significant safety risks in compounding.
Strongest evidence
Animal and cell studies only
Overview

KPV is the C-terminal tripeptide of alpha-MSH, studied for anti-inflammatory activity without the pigment effects of the parent hormone.

What researchers study it for
  • Intestinal inflammation (mouse colitis models)
  • Airway epithelial inflammation (cells)
Mechanism

Taken up by intestinal cells through the PepT1 transporter, where it reduced inflammatory signaling in models.

Evidence (3)
  1. Animal study

    PepT1 uptake and colitis (Gastroenterology 2008)

    Oral KPV reduced intestinal inflammation in mouse colitis models via PepT1-mediated uptake.[1]

  2. Animal study

    Murine IBD models (Inflamm Bowel Dis 2008)

    Anti-inflammatory potential in mouse models of inflammatory bowel disease.[2]

  3. Cells / in vitro

    Human bronchial cells (2012)

    Inhibited inflammation cues in human bronchial epithelial cells.[3]

Limitations of the evidence
  • No human studies identified.
  • Products on this site are sold for laboratory research only. They are not the medicines used in the trials above, and those results do not apply to research material.
Sources (4)
  1. 1.PepT1-mediated tripeptide KPV uptake reduces intestinal inflammationDalmasso G et al. Gastroenterology. 2008 Animal study
  2. 2.Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel diseaseKannengiesser K et al. Inflamm Bowel Dis. 2008 Animal study
  3. 3.Inhibition of cellular and systemic inflammation cues in human bronchial epithelial cells by melanocortin-related peptidesLand SC. Int J Physiol Pathophysiol Pharmacol. 2012 Cells / in vitro
  4. 4.Certain bulk drug substances for use in compounding that may present significant safety risks (lists KPV)U.S. FDA, page current as of Apr 22, 2026 Regulatory
Every published studyPubMed search: KPV OR Lys-Pro-Val(opens in a new tab)Every registered trialClinicalTrials.gov search: KPV OR Lys-Pro-Val(opens in a new tab)

Reviewed 2026-10-02. Summaries describe published research and regulatory records; they are not medical advice and do not describe how to use this product. Sold for laboratory research use only.